Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
Fiche publication
Date publication
octobre 2017
Journal
Neurology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Plavina T, Muralidharan KK, Kuesters G, Mikol D, Evans K, Subramanyam M, Nestorov I, Chen Y, Dong Q, Ho PR, Amarante D, Adams A, De Sèze J, Fox R, Gold R, Jeffery D, Kappos L, Montalban X, Weinstock-Guttman B, Hartung HP, Cree BAC
Lien Pubmed
Résumé
To characterize the reversibility of natalizumab-mediated changes in pharmacokinetics/pharmacodynamics in patients with multiple sclerosis (MS) following therapy interruption.
Mots clés
Adult, Double-Blind Method, Female, Follow-Up Studies, Humans, Immunologic Factors, blood, Integrin alpha4, blood, Lymphocyte Count, Lymphocyte Subsets, immunology, Male, Middle Aged, Multiple Sclerosis, blood, Natalizumab, blood, Retrospective Studies, Secondary Prevention, Treatment Outcome, Vascular Cell Adhesion Molecule-1, blood
Référence
Neurology. 2017 Oct 10;89(15):1584-1593